StemCell Therapy

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by investment analysts at BidaskClub from a hold rating to a sell rating in a report released on Friday, BidAskClub reports.

Several other brokerages also recently weighed in on SRPT. Robert W. Baird upped their price objective on Sarepta Therapeutics from $181.00 to $192.00 and gave the stock an outperform rating in a research report on Friday, December 20th. SVB Leerink restated a buy rating and set a $216.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, January 23rd. Nomura restated a buy rating and set a $230.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, February 25th. Barclays reaffirmed a buy rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Sunday, December 15th. Finally, Goldman Sachs Group reaffirmed a buy rating and issued a $180.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, December 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the companys stock. The company has an average rating of Buy and an average target price of $193.95.

Shares of SRPT stock opened at $94.19 on Friday. The company has a quick ratio of 4.90, a current ratio of 5.55 and a debt-to-equity ratio of 0.89. Sarepta Therapeutics has a twelve month low of $72.05 and a twelve month high of $158.80. The company has a market cap of $7.36 billion, a P/E ratio of -9.74 and a beta of 2.08. The business has a fifty day simple moving average of $117.59 and a 200 day simple moving average of $105.77.

In other news, Director Hans Lennart Rudolf Wigzell sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $116.89, for a total value of $584,450.00. Following the completion of the sale, the director now owns 18,792 shares of the companys stock, valued at $2,196,596.88. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 6.60% of the companys stock.

Several hedge funds have recently modified their holdings of SRPT. Amundi Pioneer Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 32.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology companys stock valued at $18,428,000 after buying an additional 38,194 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 34.6% in the third quarter. Envestnet Asset Management Inc. now owns 4,024 shares of the biotechnology companys stock valued at $303,000 after buying an additional 1,034 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Sarepta Therapeutics by 20.9% in the third quarter. Janney Montgomery Scott LLC now owns 4,930 shares of the biotechnology companys stock valued at $371,000 after buying an additional 852 shares during the period. Commonwealth Equity Services LLC increased its stake in shares of Sarepta Therapeutics by 15.8% in the third quarter. Commonwealth Equity Services LLC now owns 10,951 shares of the biotechnology companys stock valued at $824,000 after buying an additional 1,497 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Sarepta Therapeutics by 6.5% in the third quarter. Russell Investments Group Ltd. now owns 14,928 shares of the biotechnology companys stock valued at $1,124,000 after buying an additional 915 shares during the period. 93.82% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: Do You Need a Fiduciary?

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Originally posted here:
Sarepta Therapeutics (NASDAQ:SRPT) Cut to Sell at BidaskClub - Redmond Register

This entry was posted on March 13, 2020 at 9:46 am and is filed under Genetic medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |